Anticancer research
-
Anticancer research · Jul 1998
Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals.
Because of the observed immunostimulatory actions of a new fermented wheat germ extract--with standardized benzoquinone composition--we have investigated the eventual tumor growth- and metastasis-inhibiting effects of this preparation (Avemar) applied alone or in combination with vitamin C. Tumor models of different origin [a highly metastatic variant of the Lewis lung carcinoma (3LL-HH), B16 melanoma, a rat nephroblastoma (RWT-M) and a human colon carcinoma xenograft (HCR25)]--kept in artificially immunosuppressed mice were applied. The metastasis-inhibiting effects of the treatments have been studied both in the presence and in the absence (following surgical removal) of the transplanted primary tumors. ⋯ According to the results of other experiments--carried out in our laboratory in parallel with those described here--Avemar proved to have a meaningful immunostimulatory effect. It might therefore be suggested that the observed metastasis-inhibiting effect of this preparation may be mainly due to its immunostimulatory properties. The possible therapeutic benefits of Avemar and Avemar plus vitamin C are also discussed.
-
Anticancer research · Mar 1998
Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression.
Previous studies have demonstrated that androgen-independent prostate cancer cancer cells undergo apoptosis in response to ionizing irradiation. The p53 protein controls cell cycle arrest and apoptosis by acting as a checkpoint control that halts the cell cycle in G1, while DNA damage is present. In this study the effect of overexpression of mutant p53 protein, on radiation-induced apoptotic cell death of human prostate cancer cells PC-3 was investigated. ⋯ These findings seriously challenge the involvement of p53 in radiation-induced apoptosis in human prostate cancer cells and suggest that p53 mutations provide no selective advantage in the development of radioresistance of prostate tumor cells within the context of p53 independent apoptotic pathway.
-
Anticancer research · Sep 1997
Comparative Study Clinical TrialComparison of breast-conserving therapy with mastectomy for treatment of early breast cancer.
The aim of this study was to compare the survival and recurrence rates of patients undergoing breast-conserving therapy with the rates of those undergoing mastectomy. Between August 1991 and June 1994, 229 patients were enrolled in this study, although one was later excluded because the tumor was histologically diagnosed as benign. A total of 119 patients with clinical stage TIS, I or II underwent breast-conserving therapy and 109 patients received mastectomy. ⋯ Mean follow-up time of the breast-conserving therapy group and the mastectomy group was 42.4 and 39.7 months, respectively. There was no significant difference in the overall survival and disease-free survival between breast-conserving therapy and mastectomy. After adjustment for the clinical stage, there was no significant difference in the prognosis between breast-conserving therapy and mastectomy.
-
Anticancer research · Jul 1997
Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
The prognostic information provided by preoperative serum CEA, CA 19-9 antigen assays as compared with the classical prognostic factors (age, sex, tumor infiltration, tumor stage (Dukes') and R-classification) in 495 patients with colorectal carcinoma was analysed. ⋯ The postoperative Dukes' classification provides the best prognostic information besides the preoperative values of CA 19-9. The predictive information provided by the preoperative CA 19-9 serum level is additional to that obtained from the other factors investigated.
-
Anticancer research · Jul 1997
Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
In this study we investigated whether circadian rhythms of interleukin-2 receptors (sIL-2R), serum thymidine kinase (sTK) and beta-2-microglobulin (beta 2M) are apparent, which may influence tumor marker detection. Blood was drawn every two hours over 24 hours from 6 patients with NHL, 3 healthy donors and three patients with non-hematologic disorders. The serum levels of the three markers were measured. ⋯ The three NHL-patients with consistent circadian rhythms in all three markers achieved a complete remission, whereas the patients with disturbed rhythm progressed under therapy. We showed that circadian variations of sIL-2R, sTK and beta 2M follow a sinusoidal circadian rhythm in normals and patients with NHL. Disturbance of this rhythm may be related to a worse prognosis.